The Medicines Company (MDCO) : The Medicines Company (MDCO) had a healthy money flow of $1.42 million into the stock during the Fridays trading session. The value of bullish trades on upticks was $5.18 million, whereas, investors only sold shares worth $3.76 million on downticks. The stock closed the day with an up-down ratio of 1.38.The money flow in the block trades to the tune of $1.13 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $1.13 million worth of transactions were on upticks. The Medicines Company (MDCO) stock slid $0.66 intraday and traded at 38.31, a change of -1.69% over previous days close. However, for the week, the company shares are -3.77% compared to previous weeks close.
The company Insiders own 7.9% of The Medicines Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -14.05% . During last six month period, the net percent change held by insiders has seen a change of -14.05%.
In a related news, The Securities and Exchange Commission has divulged that Meanwell Clive, director officer (CEO) of Medicines Co /De, had unloaded 1,377 shares at an average price of $40 in a transaction dated on September 1, 2016. The total value of the transaction was worth $55,080.
The Medicines Company (NASDAQ:MDCO): stock was range-bound between the intraday low of $37.76 and the intraday high of $39.25 after having opened at $39.1 on Fridays session. The stock finally closed in the red at $39.1, a loss of -1.69%. The stock remained in the red for the whole trading day. The total traded volume was 622,445 shares. The stock failed to cross $39.25 in Fridays trading. The stocks closing price on Thursday was $38.97.
The Medicines Company (MDCO) : During the past 4 weeks, traders have been relatively bearish on The Medicines Company (MDCO), hence the stock is down -0.72% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.25% relative to the S&P 500. The 4-week change in the price of the stock is -0.85% and the stock has fallen -3.77% in the past 1 week.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.